Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Debt to Equity (2017 - 2023)

Historic Debt to Equity for Sutro Biopharma (STRO) over the last 7 years, with Q4 2023 value amounting to $0.03.

  • Sutro Biopharma's Debt to Equity fell 6380.07% to $0.03 in Q4 2023 from the same period last year, while for Dec 2023 it was $0.03, marking a year-over-year decrease of 6380.07%. This contributed to the annual value of $0.03 for FY2023, which is 6380.07% down from last year.
  • According to the latest figures from Q4 2023, Sutro Biopharma's Debt to Equity is $0.03, which was down 6380.07% from $0.06 recorded in Q3 2023.
  • Sutro Biopharma's Debt to Equity's 5-year high stood at $0.29 during Q1 2020, with a 5-year trough of $0.03 in Q4 2023.
  • Over the past 5 years, Sutro Biopharma's median Debt to Equity value was $0.09 (recorded in 2021), while the average stood at $0.1.
  • As far as peak fluctuations go, Sutro Biopharma's Debt to Equity surged by 19942.03% in 2019, and later plummeted by 7271.11% in 2021.
  • Sutro Biopharma's Debt to Equity (Quarter) stood at $0.1 in 2019, then decreased by 26.81% to $0.07 in 2020, then surged by 34.51% to $0.1 in 2021, then dropped by 24.61% to $0.07 in 2022, then tumbled by 63.8% to $0.03 in 2023.
  • Its last three reported values are $0.03 in Q4 2023, $0.06 for Q3 2023, and $0.07 during Q2 2023.